What is Renerva?
Renerva, Inc. is an innovative medical device company dedicated to enhancing healing after nerve injuries through advanced surgical solutions. Their primary focus is on developing cutting-edge technologies designed to improve nerve recovery and alleviate nerve pain. The company's flagship product, the PNM-CAP device, has achieved a significant milestone with FDA IDE approval, paving the way for first-in-human clinical trials. Currently, Renerva's offerings are investigational and not yet available for commercial use, highlighting their commitment to rigorous scientific validation and patient safety.
How much funding has Renerva raised?
Renerva has raised a total of $408K across 2 funding rounds:
Debt
$83K
Private Equity
$325K
Debt (2021): $83K with participation from PPP
Private Equity (2025): $325K, investors not publicly disclosed
Key Investors in Renerva
PPP
Public-Private Partnership
What's next for Renerva?
With the recent influx of $325K in a large-scale, late-stage funding round, Renerva is strategically positioned to accelerate its development pipeline. This substantial capital infusion is expected to fuel the progression of its PNM-CAP device through clinical trials and support further research and development efforts. The company's focus on nerve injury healing and pain alleviation addresses a critical unmet need in the medical field. Future growth will likely involve navigating regulatory pathways, scaling manufacturing capabilities, and preparing for potential market entry, contingent on successful clinical outcomes and approvals.
See full Renerva company page
